| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w17987 |
| 来源ID | Working Paper 17987 |
| The Role of Government Reimbursement in Drug Shortages | |
| Ali Yurukoglu; Eli Liebman; David B. Ridley | |
| 发表日期 | 2012-04-12 |
| 出版年 | 2012 |
| 语种 | 英语 |
| 摘要 | Beginning in the mid-2000s, the incidence of drug shortages rose, especially for generic injectable drugs such as anesthetics and chemotherapy treatments. We examine whether reimbursement changes contributed to the shortages, focusing on a reduction in Medicare Part B reimbursement to providers for drugs. We hypothesize that lower reimbursement put downward pressure on manufacturers’ prices which reduced manufacturers’ incentives to invest in capacity, reliability, and new launches. We show that, after the policy change, shortages rose more for drugs with (i) higher shares of patients insured by Medicare, (ii) greater decreases in provider reimbursement, and (iii) greater decreases in manufacturer prices. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Regulatory Economics |
| URL | https://www.nber.org/papers/w17987 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/575663 |
| 推荐引用方式 GB/T 7714 | Ali Yurukoglu,Eli Liebman,David B. Ridley. The Role of Government Reimbursement in Drug Shortages. 2012. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w17987.pdf（403KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
